Expanded Access vs. Clinical Trials: FDA Pathways Explained

By the Regenerative Evidence Guide Team

Expanded access and clinical trial participation are two different FDA pathways to an unapproved product, and confusing them is an easy, costly mistake. A clinical trial is a research study meant to generate evidence. Expanded access is a narrower, case-by-case route for one patient with a serious illness who cannot enter a trial. Neither means FDA approval.

Imagine someone finds both phrases on two different websites: “enrolled in a clinical trial” and “expanded access program.” Both sound official. Both mention the FDA. It’s easy to assume they’re interchangeable, or that either one is a safety stamp of approval. This guide breaks down what actually separates them, using the FDA’s own patient-facing guidance, so you can bring sharper questions to a licensed clinician instead of guessing from the terminology alone.

Clinical Trial vs. Expanded Access: Side-by-Side Comparison

Here is how the two pathways compare on the factors that matter most to a patient or caregiver evaluating them:

• Main purpose. Clinical trial: generate research data on safety and effectiveness. Expanded access: treat one patient who cannot wait and cannot enroll in a trial.
• Who can request it. Clinical trial: any eligible volunteer who meets the study’s entrance criteria. Expanded access: patients with a serious or immediately life-threatening illness and no comparable treatment option.
• Who has to approve it. Clinical trial: the study team, based on protocol eligibility criteria. Expanded access: the physician, the manufacturer, an Institutional Review Board (IRB), and the FDA — all five, in the FDA’s own framework.
• Is approval designed to deliver if you qualify? Clinical trial: no — enrollment can close or criteria can exclude you. Expanded access: no — the FDA states this explicitly; a company can decline even if you meet the criteria.
• Typical cost picture. Clinical trial: varies by study; some trial-related costs may be covered by the sponsor. Expanded access: usually not covered by insurance or Medicare, per the FDA.

How Does Each Pathway Actually Work?

Clinical Trial Participation, Step by Step

• A patient must meet the study’s specific entrance criteria (age, diagnosis, prior treatments, and other factors set by the researchers).
• The patient volunteers and completes an informed consent process before anything begins.
• The trial follows a research protocol, meaning visit schedules, testing, and monitoring are standardized for everyone in the study, not personalized to one patient’s preferences.
• The FDA’s supporting guidance points patients to ClinicalTrials.gov for information on studies that are currently enrolling.

Expanded Access, Step by Step

The FDA describes expanded access as a pathway for people with serious or immediately life-threatening illnesses who cannot wait for the standard approval process and cannot enroll in a clinical trial. Getting access this way depends on five separate decisions lining up, not just the patient’s willingness:

1. A licensed physician has to agree to oversee the treatment and manage all required records.
2. The company that makes the product has to agree to provide it. The FDA is explicit that no law or policy requires a company to say yes.
3. An Institutional Review Board (IRB) — an independent group that reviews research and treatment plans to protect patients — has to review and approve the plan.
4. The FDA has to review and approve the specific request.
5. The patient has to review and sign informed consent after understanding the risks.

If any one of those five steps doesn’t happen, expanded access doesn’t happen either. The FDA also notes that programs are established by manufacturers, sometimes at a doctor’s request, not by the FDA itself.

Why Do People Confuse the Two Pathways?

The mix-up usually comes from three places:

• Both involve unapproved products. Hearing “FDA” and “program” next to a treatment name can sound like a stamp of approval. It isn’t. The FDA states these products “may cause serious side effects that were not expected,” precisely because the evidence base is still incomplete.
• Both require a doctor’s involvement. But the role differs. In a trial, the doctor is typically a study investigator following a fixed protocol. In expanded access, the doctor is requesting an individualized exception, often at the patient’s or family’s request.
• Neither is designed to deliver the outcome people hope for. The FDA specifically states that meeting the criteria for expanded access does not mean a request will be granted. The company, the IRB, or the FDA can each decline.

What Doesn’t Either Pathway Promise?

These limits apply whether the conversation is about a clinical trial or an expanded access request:

• Not a safety commitment. “Investigational” means the product’s risks and benefits are still being studied. Being offered a spot in either pathway is not evidence that a product is safe for you specifically.
• Not automatically covered by insurance. The FDA notes that expanded access products and the associated care are usually not covered by insurance or Medicare, and patients may be responsible for costs. Ask about this directly before agreeing to anything.
• Not a right. Neither pathway is owed to any patient. Manufacturers decide whether to offer an expanded access program at all, and trials set their own enrollment criteria.
• Not the same as completed FDA approval. A product doesn’t need to finish full FDA review to be used through either pathway. That’s exactly why extra caution and extra questions matter here.

If you or someone you’re helping is facing an urgent medical decision or a safety concern right now, contact your treating physician directly, or call local emergency services if it’s an emergency. This article is background information, not a substitute for that conversation.

What Questions Should You Bring to Your Clinician?

Instead of trying to sort out which “official-sounding” pathway applies on your own, use this sequence with a licensed clinician who knows your full medical history:

1. Ask what pathway is actually being described. “Is this a clinical trial I would enroll in, or an expanded access request you’d be making on my behalf?” The answer changes what oversight and structure apply.
2. Ask who has to approve it. For a trial: what are the enrollment criteria, and who reviews eligibility? For expanded access: has the company agreed, has an IRB reviewed the plan, and has the FDA responded?
3. Ask what happens if a step doesn’t clear. If a trial rejects your enrollment, or the company, IRB, or FDA doesn’t approve an expanded access request, what’s the backup plan?
4. Ask about cost, in writing. Which parts, if any, would you be expected to pay for, and which might be covered by the trial sponsor or the company providing expanded access?
5. Ask what monitoring looks like. Who is responsible for tracking side effects, and how would you reach them if something felt wrong?

Bringing a written list of these five questions to an appointment is a practical way to get direct answers instead of relying on how a website or brochure describes the option.

Frequently Asked Questions

Does having a serious illness automatically qualify me for expanded access?

No. A serious or life-threatening diagnosis is one requirement, but the FDA is explicit that meeting the criteria does not commitment approval. The physician, the manufacturer, the IRB, and the FDA all have to agree separately.

Can a company refuse to give me an investigational product through expanded access?

Yes. The FDA states there is no law or policy that requires a company to provide access to an investigational product outside of a clinical trial, even when a patient otherwise qualifies.

Will my insurance pay for an expanded access treatment?

Usually not. The FDA notes that expanded access products and related care are typically not covered by insurance or Medicare, so patients may be responsible for costs. Confirm this directly before agreeing to anything.

Is expanded access the same as the FDA approving a treatment?

No. Expanded access lets a specific patient try a product that is still investigational — meaning its safety and effectiveness are not yet fully established — not a product the FDA has approved for general use.

Where can I look for a clinical trial that’s currently enrolling?

The FDA’s own guidance points patients to ClinicalTrials.gov for information on studies that are actively recruiting, alongside a conversation with your treating physician about whether you meet a given study’s criteria.

Where This Fits Into Your Research

This page focuses specifically on the difference between these two access pathways. If you’re building a broader understanding of how to evaluate regenerative-medicine information generally, our Start Here page walks through how to approach this site and this topic as a new reader. If you want to understand the sourcing standards behind pages like this one, see How We Research.

Sources and Limits of This Article

The facts in this article are drawn from two FDA patient-facing resources: the FDA’s Expanded Access: Information for Patients page and the FDA’s FAQ on accessing drugs that have not yet been approved. Where this article uses a direct FDA phrase, it is quoted rather than paraphrased as fact.

This article does not cover every FDA program related to investigational access — for example, it does not detail Right to Try law, which is a separate pathway with its own rules. It also does not address regenerative-medicine products specifically regulated as biologics or devices, which can involve additional FDA pathways not described here. Regulatory guidance can change; always confirm current requirements directly with the FDA or a licensed clinician rather than relying solely on this summary.

Medical and Educational Disclaimer

This article is for general educational purposes only. It does not provide medical advice, does not recommend any treatment, product, or provider, and is not a substitute for consultation with a licensed physician. Regenerative Evidence Guide is an independent educational publication and is not affiliated with, endorsed by, or operating as any medical academy, clinic, faculty, conference, or training program that may have previously used this domain — see our Independence and Domain History page for details. If you are facing a medical emergency, call your local emergency services immediately.

By Regenerative Evidence Guide Editorial Team